Baishao Qiwu Granules For The Treatment Of Ulcerative Colitis With Syndrome Of Damp-Heat Accumulatio

Objective:Ulcerative colitis is a common inflammatory bowel disease.With the improvement of people’s living standards in contemporary society,the incidence of this disease in China is increasing.As a treatment feature of our country,traditional Chinese medicine(TCM)is a means of treating ulcerative colitis.The main purpose of this study is to investigate the clinical efficacy of oral Baishao Qiwu granule in the treatment of ulcerative colitis with damp-heat accumulation syndrome,and to compare it with mesalazine sustained release granule,showing the therapeutic characteristics of traditional Chinese medicine,and providing a new direction for the treatment of ulcerative colitis in the future.Methods:From January 2020 to November 2022,103 patients with ulcerative colitis of damp-heat deposit syndrome treated in the Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine were selected as the research objects.According to the statistical method,103 patients were randomly divided into the treatment group and the control group.A total of 100 patients were enrolled,with 50 patients in each group.The control group was treated with mesalazine sustained-release granules,and the treatment group was treated with Baishao Qiwu granules.At the end of the study,the clinical symptoms of the patients were observed,and laboratory routine and colonoscopy were performed.The clinical symptom score,TCM syndrome efficacy evaluation,mucosal evaluation score under colonoscopy,incidence of adverse reactions,safety and recurrence rate were compared between the two groups.Results:The clinical symptom scores of the two groups were lower than those before treatment(P<0.05),and the clinical symptom scores of the treatment group were lower than those of the control group(P<0.05).The total effective rate of TCM syndrome in the treatment group was94%,which was higher than 72% in the control group,and the difference was statistically significant(P<0.05).The mucosal evaluation scores under colonoscopy were lower than those before treatment(P<0.05),and there was no significant difference in endoscopic scores between the two groups after treatment(P>0.05).The incidence of adverse reactions was 4% in the treatment group and 24% in the control group.The treatment group was lower than the control group,and the difference between the two groups was statistically significant(P<0.05).In terms of safety,the treatment group was safer than the control group(P<0.05).The recurrence rate was6% in the treatment group and 26% in the control group,and the recurrence rate in the treatment group was lower than that in the control group(P<0.05).Conclusions:Baishao Qiwu granule can improve the clinical symptoms of patients,improve the efficacy of TCM syndrome,and has a low incidence of adverse reactions,high drug safety,and low recurrence rate.Its therapeutic effect is better than mesalazine sustained-release granules.